Solubilized Keratin for Health & Longevity

Evidence Review created on 04/25/2026 using AI4L / Opus 4.7

Also known as: Cynatine HNS, Cynatine FLX, Soluble Keratin, Bioavailable Keratin, Keratin Peptides

Motivation

Solubilized keratin (also marketed as Cynatine HNS) is an orally bioavailable form of the structural protein keratin, derived from sheep’s wool or poultry feathers. The solubilization process makes ordinarily indigestible keratin available to the body via oral intake, yielding a protein with an amino acid profile close to that of human keratin.

Interest in solubilized keratin sits at the intersection of “beauty from within” supplements and the broader longevity question of whether replenishing structural proteins can offset visible signs of aging. The protein is unusually rich in cysteine, the rate-limiting precursor for glutathione synthesis, which positions it as more than a cosmetic ingredient. A small clinical literature, mostly manufacturer-sponsored, has reported improvements primarily in hair and nail health.

This review examines the evidence for solubilized keratin as a longevity-oriented intervention — what it is, where it sits within the broader supplement landscape, the scope and limits of its human data, who pays for the studies, the practical risks and tolerability profile, and the protocols and dosing regimens used by clinicians and researchers working in beauty-supplement and joint-health settings.

Benefits - Risks - Protocol - Conclusion

Grokipedia

No dedicated Grokipedia article for solubilized keratin exists as of 04/25/2026.

Examine

No dedicated Examine.com supplement page for solubilized keratin exists as of 04/25/2026.

ConsumerLab

No dedicated ConsumerLab.com review or product-testing page for solubilized keratin exists as of 04/25/2026.

Systematic Reviews

No systematic reviews or meta-analyses for solubilized keratin were found on PubMed as of 04/25/2026.

Mechanism of Action

Native keratin is among the most chemically resistant proteins in nature. Its mechanical strength comes from dense disulfide cross-links between cysteine residues, which also make it indigestible by ordinary gastrointestinal proteases. Solubilization is a controlled chemical process — typically using mild reducing agents and pH manipulation — that selectively breaks a fraction of those disulfide bonds while leaving the peptide backbone and the higher-order structure largely intact. The result is a soluble, ~83% digestible keratin that retains an amino acid profile remarkably close to human hair, nail, and skin keratin.

Once absorbed, solubilized keratin contributes to several biological pathways:

Direct substrate supply for keratinocytes (the cells that produce hair, nail, and stratum-corneum keratin) and follicular dermal cells, providing cysteine, glutamic acid, leucine, and serine in proportions matched to keratin synthesis demands
Cysteine donation for de novo glutathione synthesis. Cysteine is the rate-limiting precursor; pulse-feeding cysteine via solubilized keratin can support glutathione status alongside endogenous synthesis
Substrate for taurine synthesis from cysteine via cysteine sulfinic acid decarboxylase
In vitro, soluble keratin peptides have been shown to stimulate keratinocyte proliferation up to ~160% versus untreated controls, suggesting signaling activity beyond pure substrate provision; the receptor-level basis for this is not yet defined
Possible modulation of inflammation in joint tissues (the basis for the Cynatine FLX product line), though mechanism is less well characterized than for hair-skin-nail outcomes

Competing mechanistic interpretations exist. The strict-substrate camp argues that any oral protein hydrolysate sufficiently rich in sulfur amino acids would produce comparable effects; the bioactive-peptide camp points to in-vitro signaling activity not reproduced by free amino acid mixtures. The 2025 Tursi et al. trial of a competing free-amino-acid keratin hydrolysate (FKH) showed comparable cosmetic-endpoint improvements to Cynatine-style preparations, partially supporting the substrate view, while in-vitro proliferation differences favor the bioactive-peptide view.

Pharmacological properties:

Half-life: Plasma free-amino-acid kinetics dominate; cysteine and other constituent amino acids appear in plasma within 1–3 hours of oral dosing and are cleared on the standard plasma amino acid timescale of 4–6 hours. Tissue-level effects (keratinocyte turnover, glutathione status) accumulate over weeks
Selectivity: Not a receptor-targeted molecule; effects derive from amino acid composition and possibly intact peptide signaling
Tissue distribution: Distributed via plasma amino acid pool; preferentially incorporated into rapidly turning-over keratinocytes (skin epidermis, hair follicle matrix, nail matrix) and into glutathione-synthesizing tissues (liver primarily)
Metabolism: Standard proteolytic digestion in the small intestine yields free amino acids and short peptides; no specialized metabolic pathway. Excretion is via the standard urea cycle and amino acid catabolism

Historical Context & Evolution

Keratin was first described as a protein class in the early 19th century, but its dense disulfide cross-linking made it a notorious example of an indigestible structural protein. For most of the 20th century, keratin from wool, hooves, feathers, and hair was treated as an industrial waste product or used in low-value applications such as fertilizer, fire-retardant foams, and animal feed extenders, despite its nutrient-dense amino acid profile.

The development of solubilized keratin grew out of two distinct lines of research. In New Zealand, agricultural-science work on processing wool and meat-industry byproducts produced the first practical “Keratec” solubilization process in the early 2000s, with the goal of converting low-value wool into a high-value nutraceutical. In parallel, biomaterials laboratories worked on solubilizing human hair keratin for wound dressings and tissue scaffolds. The dietary-supplement application — branded as Cynatine and licensed by Roxlor LLC — emerged from the agricultural lineage and was protected by U.S. Patent 7,838,042 (with related international filings).

The first manufacturer-sponsored randomized controlled trials appeared in 2013 (skin) and 2014 (hair and nails), reporting statistically significant improvements at 500 mg/day over 90 days. A separate 2013 trial of Cynatine FLX in knee osteoarthritis reported pain and stiffness reductions. A 2018 New Zealand cycling-performance trial — the only independent academic trial — found increased lean leg mass but no ergogenic effect. A 2025 Italian trial of a different free-amino-acid keratin hydrolysate (FKH) reported similar cosmetic benefits, suggesting the active mechanism may be substrate provision more than intact peptide bioactivity.

Scientific opinion has neither dismissed nor fully embraced the compound. Mainstream dermatology guidance (e.g., Zaraa & Richert, 2025) acknowledges solubilized keratin as one of several supplement options for nail health alongside biotin, collagen peptides, MSM, and orthosilicic acid, while noting the dominance of manufacturer-sponsored evidence and the absence of independent replication for most cosmetic endpoints.

Expected Benefits

A dedicated search for solubilized keratin’s complete benefit profile was performed across PubMed, manufacturer technical literature, examine.com, and the Life Extension archive before drafting this section.

High 🟩 🟩 🟩

No benefits of “High” evidence level have been established for solubilized keratin; all human cosmetic-endpoint findings rest on single industry-sponsored randomized controlled trials and have not been independently replicated outside the manufacturer ecosystem.

Medium 🟩 🟩

Improvement in Hair Loss, Strength, and Luster

The 2014 Beer et al. randomized double-blind placebo-controlled trial (sponsored by Roxlor LLC, the Cynatine HNS manufacturer — a direct financial conflict of interest) in 50 women showed statistically significant improvements in hair loss rate, hair strength (tensile measurement), amino acid composition of the hair shaft, and hair luster after 90 days of 500 mg/day Cynatine HNS plus a vitamin/mineral cofactor blend. Hair loss during washing was reduced approximately 30%, and hair strength increased approximately 12% versus placebo. The trial used objective, instrumented endpoints. The 2025 Tursi et al. trial of a different keratin hydrolysate (FKH, sponsored by BCF Life Sciences — also a direct manufacturer conflict of interest) reproduced the directional finding using a chemically distinct preparation, supporting the underlying signal.

Magnitude: ~30% reduction in hairs lost during washing; ~12% increase in hair tensile strength at 90 days; significant increases in cuticle amino acid content.

Improvement in Brittle Nails

The same 2014 Beer et al. trial reported an 87.5% improvement in the tendency of nails to break in the active group versus 28.5% in placebo, alongside instrumented improvements in nail strength and appearance. The 2025 Zaraa & Richert dermatology review classifies solubilized keratin alongside biotin, collagen peptides, MSM, and orthosilicic acid as having clinical evidence for improving nail brittleness.

Magnitude: 87.5% vs. 28.5% subjective improvement in tendency to break; instrumented nail strength improvements at 90 days.

Skin Hydration, Elasticity, and Wrinkle Reduction

The 2013 Beer et al. randomized double-blind placebo-controlled trial in 50 women reported statistically significant improvements in skin moisture, elasticity, wrinkle depth, smoothness, and overall appearance after 90 days of 500 mg/day Cynatine HNS. Approximately 11.5% reduction in wrinkle appearance was reported. The 2025 Tursi et al. trial of a free-amino-acid keratin hydrolysate (FKH, 500 or 1000 mg/day for 90 days) reproduced significant improvements across nearly all skin parameters in 100+ women using a chemically distinct preparation.

Magnitude: ~11.5% reduction in wrinkle appearance; double-digit percentage improvements in instrumented skin moisture and elasticity at 90 days.

Joint Pain and Stiffness Reduction in Knee Osteoarthritis

The 2013 Beer et al. randomized double-blind placebo-controlled trial of Cynatine FLX (500 mg/day for 60 days) in 50 adults with knee osteoarthritis reported approximately 2× greater reductions in WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index — a standardized osteoarthritis symptom rating scale) pain scores versus placebo, with comparable reductions in stiffness. Onset of symptom improvement occurred within approximately six days. Mechanism is hypothesized to be cysteine-driven glutathione support plus possible direct anti-inflammatory effects in joint tissue. Single trial; not independently replicated.

Magnitude: ~2× greater pain-score reduction vs. placebo at 60 days on WOMAC; ~13% improvement in pain at 6 days.

Low 🟩

Increase in Lean Leg Mass in Trained Men

The 2018 Crum et al. crossover trial in 15 endurance-trained men found that 4 weeks of 0.8 g/kg/day soluble keratin produced a significantly greater increase in DEXA (dual-energy X-ray absorptiometry — a body composition imaging method) measured leg lean mass (+0.45 ± 0.54 kg) versus equivalent casein protein, despite no change in cycling performance, oxygen consumption, or blood parameters. The result is intriguing but isolated, sex-restricted, and short-duration. The mechanism may involve cysteine-rich amino acid composition supporting muscle structural protein turnover.

Magnitude: +0.45 kg leg lean mass over 4 weeks vs. casein control; total body composition unchanged.

Glutathione and Taurine Substrate Support

Mechanistic studies and amino acid composition analyses indicate solubilized keratin is unusually rich in cysteine (often as cysteic acid), the rate-limiting precursor for glutathione and taurine synthesis. No randomized controlled trial in humans has measured plasma or tissue glutathione directly with solubilized keratin as the test article, but the substrate-level rationale is well-grounded and parallels the established literature for N-acetylcysteine (NAC). The benefit is mechanistic and indirect.

Magnitude: Not quantified in available studies.

Speculative 🟨

Healthspan Extension via Structural-Protein Replenishment

No human data demonstrate effects on lifespan, healthspan composites, or specific aging biomarkers (epigenetic age, telomere length). The framing in industry and Life Extension communications — that supplemental keratin offsets age-related decline in endogenous structural protein synthesis — is mechanistically reasonable but supported only by surrogate cosmetic endpoints. Basis is mechanistic and surrogate-marker only at present.

Connective Tissue and Tendon Resilience

Mechanistically plausible based on cysteine-rich amino acid supply and the joint-health signal from the Cynatine FLX trial. No randomized human trial has tested tendon, ligament, or fascia outcomes directly. Basis is indirect and mechanistic.

Wound Healing and Skin Repair

Strong preclinical and biomaterials data show soluble keratin scaffolds and hydrogels accelerate wound closure and tissue regeneration. No randomized human trial has tested oral solubilized keratin for wound healing as a primary endpoint. Basis is preclinical only for the oral form.

Benefit-Modifying Factors

Baseline protein and sulfur amino acid status: Adults consuming below recommended dietary protein intake — particularly older adults or those on plant-only diets without complementary protein planning — appear to derive larger benefits because their endogenous keratin and glutathione synthesis is more substrate-limited. Adults already consuming abundant cysteine-rich protein (eggs, whey, animal protein) may see smaller incremental effects.
Baseline biomarker levels: Pre-treatment biomarkers can identify subgroups likely to derive larger benefit. Low baseline ferritin (<50 ng/mL), suboptimal 25-OH vitamin D (<30 ng/mL), low plasma zinc (<90 μg/dL), low total protein/albumin, and elevated hs-CRP (high-sensitivity C-reactive protein — sensitive marker of low-grade systemic inflammation) all reflect deficits in tissues that solubilized keratin’s substrate provision can partially address; users with these baseline values often show larger absolute hair, skin, and nail responses. Conversely, users with optimal baseline values across these markers may see smaller incremental benefit.
Age: Endogenous keratin and collagen production declines with age, particularly after 40, expanding the room for benefit. Most published trials enrolled women aged 30–65; effects in adults under 30 are largely undocumented and likely smaller given intact endogenous synthesis.
Sex-based differences: All cosmetic-endpoint trials enrolled women only; the joint-health and cycling trials included both sexes or men only. Whether men experience comparable hair, skin, and nail effects is not directly established by trial data; mechanistic considerations favor similar response, but trial-level evidence is sex-restricted.
Hair, skin, and nail baseline status: People starting from poorer baseline (visible thinning, brittle nails, advanced photoaging, dry hair) show larger absolute improvements; those with optimal baseline see smaller percentage changes.
Pre-existing health conditions: Individuals with chronic inflammatory conditions, malabsorption (celiac, IBD (inflammatory bowel disease — chronic gut inflammation including Crohn’s and ulcerative colitis), post-bariatric surgery), or hypothyroidism may have an exaggerated benefit from substrate-level support but are typically also receiving multiple confounding interventions, complicating attribution.
Concomitant micronutrient cofactor status: All Cynatine HNS trials co-administered zinc, copper, biotin, niacin, pantothenate, and pyridoxine. The independent contribution of solubilized keratin versus the cofactor stack is not cleanly separated in any trial; users with adequate baseline status of these cofactors may see smaller incremental benefits.
Genetic polymorphisms in sulfur amino acid metabolism: Variants in CBS (cystathionine β-synthase — converts homocysteine to cystathionine) and MTHFR (methylenetetrahydrofolate reductase — folate-dependent methylation enzyme) influence cysteine flux through the transsulfuration pathway and may modulate the magnitude of benefit derived from cysteine-rich substrate. Individuals with reduced-function MTHFR variants (e.g., C677T) or CBS deficiency may theoretically show altered glutathione and downstream cosmetic responses, though no trial has stratified by genotype.

Potential Risks & Side Effects

A dedicated search for the full risk and side-effect profile was performed across PubMed, FDA adverse event reporting, drugs.com, examine.com, and major drug references before drafting this section. Solubilized keratin is one of the better-tolerated supplements in this category, with no reported serious adverse events at therapeutic doses across published trials.

High 🟥 🟥 🟥

No adverse effects of “High” evidence level have been reported for solubilized keratin in published human trials.

Medium 🟥 🟥

Mild Gastrointestinal Effects

Mild gastrointestinal effects — flatulence with a sulfur odor, mild bloating, and occasional loose stools — have been reported anecdotally and in trial debrief data, attributable to the high cysteine content and resulting hydrogen sulfide production by colonic microbes. Generally mild, dose-related, and resolves with continued use, dose reduction, or splitting the dose with meals.

Magnitude: Not quantified in available studies.

Low 🟥

Allergic Reaction (Wool, Feather, or Cysteine Sensitivity)

Solubilized keratin sourced from sheep’s wool (Cynatine) or poultry feathers (FKH) carries a theoretical risk of allergic reaction in individuals with documented wool, feather, or animal-protein allergies. Case reports are not published in the peer-reviewed literature, but manufacturer cautions are standard. Individuals with severe atopy (a genetic predisposition to allergic conditions such as eczema, hay fever, and asthma) should introduce the supplement cautiously.

Magnitude: Not quantified in available studies.

Sulfur Amino Acid Load in Specific Metabolic Disorders

Individuals with rare inborn errors of sulfur amino acid metabolism — homocystinuria (a genetic disorder causing toxic homocysteine accumulation), sulfite oxidase deficiency (impaired conversion of sulfite to sulfate, causing neurological injury), and molybdenum cofactor deficiency (failure to produce the cofactor required for sulfite oxidase and related enzymes) — may have impaired clearance of cysteine and methionine; solubilized keratin’s high sulfur amino acid content could theoretically exacerbate these conditions. Clinical case reports are not available.

Magnitude: Not quantified in available studies.

Nutricosmetic Stack Interactions

The marketed Cynatine HNS product co-administers biotin (typically 150 μg). Very high biotin intake (≥5 mg/day) is known to interfere with thyroid panel, troponin, and other immunoassays; the clinical-trial dose is well below this threshold, but consumer-stack combinations with separate high-dose biotin supplements can reach interference range.

Magnitude: Not quantified in available studies.

Speculative 🟨

Pro-oxidant Effects at Supraphysiologic Cysteine Doses

Cell-culture and animal data on free cysteine (not solubilized keratin specifically) suggest pro-oxidant behavior at very high doses, theoretically achievable only with sustained mega-dosing far above the 500–1000 mg/day human protocol. No human reports at typical therapeutic doses.

Theoretical Iodine-Trapping Effects

Sulfur amino acid loading has been hypothesized to compete with iodine uptake at very high doses. Not demonstrated in humans at therapeutic solubilized keratin doses; basis is mechanistic only.

Risk-Modifying Factors

Wool or feather allergy: Documented sheep’s-wool or poultry-feather allergies represent a relative contraindication for the corresponding product source; cross-source switching (wool-derived vs. feather-derived) can sometimes resolve specific allergic triggers.
Pregnancy and breastfeeding: Solubilized keratin has not been studied in pregnancy or lactation. Most manufacturers caution against use during pregnancy on a precautionary basis. Note that this is distinct from topical “keratin treatments” used in salons (which carry separate formaldehyde-related concerns).
Pre-existing hypersensitivity to high-sulfur supplements (NAC, MSM): Individuals who have experienced gastrointestinal (GI) intolerance to NAC or MSM may have similar reactions to solubilized keratin; reduced starting doses are commonly used in this subgroup in published protocols.
Baseline biomarker levels: Elevated baseline homocysteine (>15 μmol/L) or pre-existing hypothyroidism with abnormal TSH (thyroid stimulating hormone — pituitary signal regulating thyroid output) may signal heightened sensitivity to a high cysteine load and to immunoassay interference from co-administered biotin; baseline measurement informs whether to adjust dose, separate timing from labs, or proceed with closer monitoring.
Sex-based differences: No clinically established differences in adverse-event profile between men and women, though all cosmetic-endpoint trials enrolled women only.
Pre-existing inborn errors of sulfur amino acid metabolism: Homocystinuria, sulfite oxidase deficiency, molybdenum cofactor deficiency — relative contraindications pending specialist evaluation.
Age and frailty: Older adults with reduced gastric acid secretion may have less efficient amino acid release from any oral protein; effect on solubilized keratin specifically is undocumented but plausible.
Concomitant nutricosmetic stacking: Combining solubilized keratin (which already contains low-dose biotin) with separate high-dose biotin (≥5 mg/day) supplements is associated with immunoassay interference for thyroid, troponin, and similar tests; published guidance pauses biotin 24–72 hours before such testing.
Genetic polymorphisms in sulfur amino acid clearance: Reduced-function variants in CBS (cystathionine β-synthase — initiates the transsulfuration pathway), SUOX (sulfite oxidase — oxidizes sulfite to sulfate), and MOCS1/MOCS2 (molybdenum cofactor synthesis genes) can impair clearance of cysteine and downstream sulfur metabolites. Although severe forms present clinically, milder heterozygous variants may theoretically increase sensitivity to high cysteine loads from solubilized keratin; clinical case data at typical therapeutic doses are not available.

Key Interactions & Contraindications

Levothyroxine and other amino acid-competing oral medications: Caution. Concentrated free amino acid loads can theoretically reduce levothyroxine absorption when taken simultaneously. Practical mitigation: separate dosing by ≥4 hours, with levothyroxine taken on an empty stomach in the morning and solubilized keratin taken later in the day.
L-DOPA (carbidopa-levodopa for Parkinson’s disease): Caution. Large-neutral-amino-acid competition can blunt L-DOPA absorption from the gut and across the blood-brain barrier. Separate dosing by ≥1–2 hours.
High-dose biotin supplements (≥5 mg/day): Caution. Cynatine HNS already includes biotin (typically 150 μg); stacking with separate high-dose biotin can interfere with thyroid panel (TSH, free T3 (triiodothyronine — active thyroid hormone), free T4 (thyroxine — primary circulating thyroid hormone)), troponin, parathyroid hormone, and 25-hydroxyvitamin D immunoassays. Mitigation: pause biotin 24–72 hours before laboratory testing and notify the lab of supplement use.
N-acetylcysteine (NAC), MSM (methylsulfonylmethane — an organic sulfur compound used for joint and skin support), and other high-sulfur supplements: Additive effect on cysteine and sulfur amino acid pool. Not a contraindication; combined use is common in joint-health and antioxidant stacks. Monitor for sulfur-odor flatulence.
Glutathione and glutathione precursors: Additive effects on the antioxidant system; redundant pathway activation with diminishing returns at high stack doses.
Iron supplements: Sulfur amino acids can theoretically chelate divalent metals; clinical relevance at therapeutic solubilized keratin doses is small. Routine iron supplementation does not require timing separation in published protocols.
Anticoagulants (warfarin, apixaban, dabigatran) and antiplatelet drugs (clopidogrel, aspirin): No known clinically meaningful interaction at typical doses. Routine monitoring not required for solubilized keratin alone.
Topical keratin treatments (salon hair smoothing, formaldehyde-based products): Distinct exposure pathway with its own (different) risk profile (formaldehyde inhalation). Oral solubilized keratin is not equivalent to and should not be confused with these professional treatments.
Populations who should avoid: Individuals with documented IgE (immunoglobulin E — antibody class that mediates classic allergic reactions)-mediated wool, feather, or animal-protein allergy matching the product source (absolute contraindication for that source); individuals with severe inborn errors of sulfur amino acid metabolism (homocystinuria with plasma homocysteine >100 μmol/L, sulfite oxidase deficiency, molybdenum cofactor deficiency) without specialist guidance; pregnant women across all trimesters and breastfeeding women on a precautionary basis given absence of trial data; children under 18 years (no pediatric trial data).

Risk Mitigation Strategies

Slow titration: Start at one oral dose unit (typically 250 mg) for 1 week before escalating to the full 500 mg/day. Mitigates the gastrointestinal (GI) side-effect risk that affects a minority of users; allows early identification of intolerance before committing to a 90-day course.
Take with food: Take with breakfast to reduce sulfur-odor flatulence and improve tolerability; matches the dosing schedule used in the published Cynatine HNS trials (two oral dose units with breakfast).
Timing separation: Separate from levothyroxine and L-DOPA dosing by ≥4 hours. Mitigates the small but theoretically meaningful absorption-competition interaction with these narrow-therapeutic-window drugs.
Pause biotin before lab tests: Stop separate high-dose biotin supplements 24–72 hours before laboratory testing. Mitigates immunoassay interference (TSH, troponin, PTH (parathyroid hormone — regulates calcium and bone metabolism), 25-OH-D) that can produce spurious results.
Source verification: Match product source against personal allergy history. Wool-derived (Cynatine) and feather-derived (FKH) preparations have distinct allergen profiles; switching source can sometimes resolve specific reactions.
90-day evaluation horizon: Plan a 90-day trial and discontinue if no benefit. Mitigates the sunk-cost trap of indefinite supplementation in non-responders. Published trials show maximal cosmetic effects at 60–90 days; continued supplementation beyond that without observable benefit has no supporting evidence.
Avoid in pregnancy and lactation: Mitigates the unknown-safety-data risk by deferring use until after the gestational and lactation period.
Pre-TSH stack review: Re-evaluate combined biotin and keratin stacks before TSH testing. Particularly relevant for users with known thyroid disease using both Cynatine HNS (low-dose biotin) and a separate high-dose biotin supplement.

Therapeutic Protocol

The standard protocol established in the published clinical trials is 500 mg/day of solubilized keratin (typically Cynatine HNS) for at least 90 days, taken as two 250-mg oral dose units with breakfast. Each Cynatine HNS oral dose unit typically also contains a vitamin/mineral cofactor blend (zinc 7.5 mg, copper 0.825 mg, biotin 150 μg, niacin 9 mg, pantothenate 6.84 mg, pyridoxine 1 mg).

Cosmetic indications (hair, skin, nails): 500 mg/day Cynatine HNS for 90 days minimum, with continued use for maintenance. Used in the original 2013/2014 Roxlor-sponsored trials and in subsequent commercial formulations (LYMA, NOW Foods Clinical Hair Skin & Nails, Life Extension Hair Skin & Nails Collagen Plus, NatureCity TrueHNS).
Joint indications (knee osteoarthritis): 500 mg/day Cynatine FLX for 60 days minimum. Used in the 2013 Roxlor-sponsored knee osteoarthritis trial.
Sports nutrition / lean mass: 0.8 g/kg/day soluble keratin as a partial protein-source replacement, used in the 2018 Crum et al. trial; this is far above the cosmetic-indication dose and was administered as a protein supplement rather than an adjunct.
Combined approach: Most commercially available products bundle solubilized keratin with collagen peptides, biotin, silica, and zinc. Whether this stack outperforms solubilized keratin alone is not directly tested in any controlled trial.

Competing approaches exist regarding source. Cynatine (wool-derived) is the most studied source, but the 2025 Tursi et al. trial of a poultry-feather-derived free-amino-acid keratin hydrolysate (FKH, sourced from BCF Life Sciences, marketed as Keratine Forte) reproduced cosmetic-endpoint improvements. This suggests source is less critical than total bioavailable cysteine and amino acid composition, but no head-to-head comparison exists.

Best time of day: Morning, with food, as used in published trials. No evidence supports evening or late-day dosing; sulfur-odor flatulence is more socially manageable when timed early in the day.
Half-life and dosing schedule: Constituent free amino acids appear in plasma within 1–3 hours; supplemental amino acids are cleared on the standard plasma timescale of 4–6 hours. Once-daily dosing is standard in trials. Some commercial protocols split into morning and afternoon doses to maintain a steadier amino acid pool, but no controlled trial has shown this is superior.
Single vs. split dose: Single morning dose is standard. Split dosing may improve tolerability for users who experience GI discomfort with the full 500 mg.
Genetic considerations: No formal pharmacogenetic studies. Theoretical considerations include CBS (cystathionine β-synthase) and MTHFR (methylenetetrahydrofolate reductase) polymorphisms, which influence sulfur amino acid metabolism, but no clinical trial has stratified by genotype.
Sex-based differences: All cosmetic trials enrolled women; the 2018 sports trial enrolled men only. No established sex-specific dose adjustment, but the lean-mass effect should not be assumed in women without further data.
Age-related considerations: Older adults are typical responders given declining endogenous keratin synthesis. No age-based dose reduction is established. Older adults with reduced gastric acid may benefit from taking the supplement with a protein-containing meal to optimize digestion.
Baseline biomarker considerations: No published biomarker-stratification protocol. Practical biomarker checks (TSH, hs-CRP (high-sensitivity C-reactive protein — sensitive marker of low-grade systemic inflammation), ferritin) at baseline and 90 days are reasonable for users with thyroid or inflammatory comorbidity.
Pre-existing condition considerations: Wool/feather allergy (source choice), inborn errors of sulfur amino acid metabolism (specialist consultation), pregnancy/lactation (avoid), and concurrent levothyroxine or L-DOPA therapy (timing separation) require individualized adjustments.

Discontinuation & Cycling

Lifelong vs. short-term: No defined treatment duration in industry recommendations beyond the 90-day trial-evidence base. Cosmetic improvements appear to plateau around 90 days; whether they persist beyond that with continued use, or fade upon discontinuation, has not been formally tested. Most commercial protocols treat it as ongoing, similar to collagen peptide supplementation.
Withdrawal effects: No physiological dependence or withdrawal syndrome described. Stopping use returns hair-loss rate, nail brittleness, and skin parameters to pre-treatment baseline over an unspecified timescale (mechanistically, on the order of weeks to months as keratinized tissues turn over).
Tapering protocol: Tapering is not required. The compound can be discontinued abruptly without rebound effects.
Cycling: No clear evidence supports or refutes cycling. Some practitioners cycle (e.g., 90 days on, 30 days off) on the theory of preserving response or assessing underlying baseline, but no controlled human studies have demonstrated either benefit or tachyphylaxis. Most published protocols use continuous daily dosing for the trial period and beyond.

Sourcing and Quality

Source forms: Solubilized keratin reaches the user in three principal forms — (1) Cynatine HNS / Cynatine FLX (wool-derived, Roxlor LLC, U.S. Patent 7,838,042), (2) feather-derived keratin hydrolysate (FKH, BCF Life Sciences, primarily as a free-amino-acid mix), (3) generic “keratin” supplements that may use lower-grade or undisclosed processing methods. Each has distinct quality considerations.
What to look for in supplements: The most important specification is whether the product is solubilized via a controlled disulfide-reduction process (preserving peptide structure) or simply hydrolyzed to free amino acids. Both can deliver cosmetic benefit but should not be conflated. Look for product labels that specify the branded ingredient (Cynatine, FKH/Keratine Forte) and dose; “keratin” without specification of process and source is largely uninterpretable. Third-party testing (NSF, USP, ConsumerLab, or independent COA (Certificate of Analysis — a third-party document verifying the contents and purity of a product batch)) confirms label accuracy and screens for heavy metals and microbial contamination.
Reputable products and brands: Cynatine HNS is included in NOW Foods Clinical Hair Skin & Nails, LYMA Supplement, Life Extension Hair Skin & Nails Collagen Plus, Radiant Life Premier Hair Skin & Nails, and NatureCity TrueHNS. Cynatine FLX is sold standalone for joint indications. FKH-based products (BCF Life Sciences) are predominantly European.
Process distinctions: “Solubilized” keratin retains intact peptide structure; “hydrolyzed” keratin is degraded further to peptides and free amino acids; “keratin extract” is a general term covering both. The 2025 Tursi et al. data suggest the cosmetic-endpoint difference between intact-peptide and free-amino-acid forms is small, but the underlying mechanism may differ.
Cost considerations: Branded Cynatine HNS products cost approximately $30–60 per month at therapeutic doses. Generic “keratin” supplements without branded ingredient identification are cheaper but their composition and bioavailability are not characterized in trials.

Practical Considerations

Time to effect: Hair shedding rate begins to decrease at 30–60 days; nail brittleness improves at 60–90 days; skin moisture and elasticity changes are detectable at 30 days and continue to accumulate to 90 days. Joint-pain reduction in the Cynatine FLX trial began within 6 days. Subjective reports of improved hair luster typically appear at 4–8 weeks. Glutathione-pathway effects (mechanistic) are presumably faster but not measured in human trials of this product.
Common pitfalls: (1) Using unbranded “keratin” supplements without confirming source, process, or dose. (2) Discontinuing before the 90-day mark (effects accumulate). (3) Assuming oral solubilized keratin is equivalent to topical keratin hair treatments — they are entirely different products. (4) Stacking solubilized keratin with separate high-dose biotin without awareness of immunoassay interference. (5) Expecting hair regrowth in pattern hair loss (androgenetic alopecia — hormonally driven male- or female-pattern hair thinning) — solubilized keratin is not an androgen-pathway intervention and does not address the dominant cause of male and female pattern hair loss.
Regulatory status: Solubilized keratin is sold as a dietary supplement in the United States, Europe, Japan, and most major jurisdictions. Not approved by the FDA for any disease indication. Cynatine ingredients are GRAS (Generally Recognized as Safe) for use as food supplements. Off-label use by clinicians is common but not formally regulated.
Cost and accessibility: Branded Cynatine HNS products cost approximately $30–60 per month. Generic keratin supplements cost less but lack the published trial data tied to branded ingredients. Availability is broad through online retailers and specialty supplement chains.

Interaction with Foundational Habits

Sleep: No direct interaction. Solubilized keratin is not stimulatory and does not appear in any reports to disrupt sleep at any dose. Indirect potentiating interaction is plausible: improved hair, skin, and nail status may secondarily improve subjective wellbeing in some users, though this is anecdotal.
Nutrition: Direct potentiating interaction. Solubilized keratin is functionally a high-cysteine protein supplement; total dietary protein adequacy and broader sulfur-amino-acid intake (eggs, animal protein, alliums, cruciferous vegetables) influence baseline status and likely modulate response. Plant-only diets without complementary protein planning may show larger absolute benefits. No specific food avoidance is required.
Exercise: Direct interaction. The 2018 Crum et al. trial showed lean leg mass increase in trained men taking 0.8 g/kg/day soluble keratin versus casein, suggesting a subtle anabolic interaction, though cycling-performance endpoints did not change. There is no evidence that solubilized keratin blunts hypertrophy or training adaptations. Timing relative to workouts has not been studied in cosmetic-dose protocols.
Stress management: Indirect interaction. Chronic psychological stress increases hair shedding (telogen effluvium — diffuse hair shedding triggered by physiological or psychological stress) and accelerates skin aging through cortisol- and inflammation-mediated pathways; solubilized keratin addresses downstream substrate availability but does not modulate the stress response itself. No specific dose-timing interaction with stress management practices has been described.

Monitoring Protocol & Defining Success

Baseline testing before initiating solubilized keratin, in published protocols, is used primarily to establish thyroid status (given the biotin co-administration and theoretical sulfur amino acid effects on iodine handling), iron status (relevant to hair shedding diagnostics), and inflammatory markers. The biomarker panel below provides the framework for response and the practical safety floor.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
TSH	0.5–2.5 mIU/L	Excludes thyroid contribution to hair/skin/nail symptoms	TSH = thyroid stimulating hormone. Conventional reference: 0.4–4.5 mIU/L. Pause separate high-dose biotin 24–72 h before testing
Free T4	1.0–1.5 ng/dL	Confirms adequate thyroid hormone production	Pair with TSH
Ferritin	50–150 ng/mL (functional target)	Iron deficiency is a leading cause of hair shedding and brittle nails	Conventional reference is wider (15–200 ng/mL for women); functional medicine targets are tighter for hair-shedding indications
25-OH vitamin D	40–60 ng/mL	Vitamin D deficiency is associated with telogen effluvium and skin barrier dysfunction	Pause high-dose biotin 24–72 h before testing
Zinc	90–135 μg/dL	Zinc deficiency causes hair loss and nail abnormalities; cofactor in keratin synthesis	Plasma zinc is fasting-sensitive
hs-CRP	< 1.0 mg/L	General marker of systemic inflammation; tracks anti-inflammatory effects of cysteine-rich supplements	hs-CRP = high-sensitivity C-reactive protein. Avoid testing during acute illness
Comprehensive Metabolic Panel	Standard ranges	Renal and hepatic baseline	Includes creatinine, eGFR (estimated glomerular filtration rate — kidney filtering capacity), liver enzymes
Total protein and albumin	6.0–8.3 g/dL / 3.8–5.0 g/dL	Identifies baseline protein-status limitations	Pair with dietary protein assessment

Ongoing monitoring follows a cadence of baseline, 90 days after initiation, and then annually if the supplement is continued. The 90-day timepoint is the natural decision point given trial data; users without observable hair, skin, or nail improvement at 90 days have weak grounds for indefinite continuation.

Qualitative markers complementing the lab panel include:

Subjective hair shedding count (per shower, per brushing)
Nail growth rate and tendency to split, peel, or break
Skin hydration, smoothness, and self-reported elasticity
Visible hair luster and broken-shaft frequency
Subjective joint comfort (for FLX users)
Sulfur-odor flatulence frequency (tolerability marker)

Emerging Research

Ongoing clinical trials (clinicaltrials.gov): A search of clinicaltrials.gov as of 04/25/2026 returned no actively recruiting or enrolling randomized controlled trials of solubilized keratin or Cynatine-branded products for hair, skin, nail, or joint indications. The absence of any registered ongoing trial outside the industry-sponsored 2013–2014 cohort is itself an important feature of the evidence landscape.
Recombinant keratin microneedles: Zhang et al., 2024 — water-soluble recombinant human keratin variants (K31/K81) designed by QTY-code methodology and delivered via microneedles activated PI3K/AKT/NF-κB signaling (an intracellular pathway regulating cell growth, survival, and inflammatory responses), increased hair-follicle anagen entry by >40% at day 12, and outperformed minoxidil in mouse models. Translational target is human androgenetic alopecia. No NCT registered yet.
FKH skin-aging trial: Tursi et al., 2025 — randomized double-blind placebo-controlled trial in 100+ adult women showed improvements across skin aging parameters at both 500 mg/day and 1000 mg/day FKH. Expands the evidence base from intact-peptide Cynatine to free-amino-acid forms, supporting a primarily-substrate mechanism.
Keratin self-assembly: Lai et al., 2021 — characterized how solubilized human hair keratin reassembles into intermediate filaments and oligomeric structures in solution, foundational for next-generation oral and topical formulations.
Keratin wound healing: Konop et al., 2021 — synthesizes the broader keratin-biomaterial literature with implications for systemic effects of orally bioavailable keratin.
Independent replication gap: No registered randomized controlled trials of solubilized keratin (or Cynatine specifically) for hair, skin, or nail outcomes are currently active or recruiting on clinicaltrials.gov as of 04/25/2026. The dependence on three industry-sponsored trials from 2013–2014 remains the central methodological limitation; independent replication has been called for in the dermatology literature (Zaraa & Richert, 2025).
Counter-evidence: The 2018 Crum et al. cycling trial — the only trial fully independent of Roxlor / BCF Life Sciences sponsorship — found no ergogenic effect despite the lean-mass change, weakening claims for solubilized keratin as a sports-nutrition intervention. The accumulating null evidence on performance contrasts with the positive cosmetic-endpoint literature.
Sponsor-bias concern: The major systematic methodological issue across the existing solubilized keratin literature is sponsor bias. All five positive cosmetic-endpoint randomized controlled trials (Beer 2013 skin, Beer 2014 hair-nails, Beer 2013 FLX, Tursi 2025 FKH skin, plus an industry abstract pool) involve a financial relationship between the trial team and the keratin ingredient manufacturer. This is a structural feature of the supplement-research economy rather than a unique feature of solubilized keratin, but the absence of any independent replication outside the 2018 cycling trial is unusually pronounced.

Conclusion

Solubilized keratin is an orally bioavailable form of the structural protein keratin, derived from sheep’s wool or poultry feathers and processed to overcome the indigestibility of native keratin. For health- and longevity-oriented adults, the most consistently demonstrated human effects are improved hair shedding rate and luster, reduced nail brittleness, and modest improvements in skin moisture, elasticity, and wrinkle appearance — all observed at a daily dose of 500 mg over 90 days. A separate signal supports reductions in knee osteoarthritis pain and stiffness, and a single independent academic trial reported a small increase in lean leg mass in trained men. The principal practical considerations are mild, infrequent sulfur-related gastrointestinal effects, the absence of safety data in pregnancy and lactation, and timing separation from thyroid hormone and Parkinson’s-disease medications. The compound is unusually rich in cysteine, providing substrate for endogenous glutathione synthesis, but human glutathione data tied to this specific product are absent. The evidence base is uneven: clinically meaningful and reproducible across two distinct manufacturer ingredient lines on cosmetic endpoints, while remaining heavily dominated by industry-sponsored trials. A notable conflict-of-interest consideration is that essentially all positive cosmetic-endpoint trials originate from teams with a direct financial relationship to the keratin ingredient manufacturers, which shapes both product visibility and the design of clinical evidence. Source forms and ingredient branding vary substantially across the marketplace, and the human evidence base is weighted toward 60–90-day endpoints rather than longer durations.

Top - Benefits - Risks - Protocol

Solubilized Keratin for Health & Longevity

Motivation

Recommended Reading

Grokipedia

Examine

ConsumerLab

Systematic Reviews

Mechanism of Action

Historical Context & Evolution

Expected Benefits

High 🟩 🟩 🟩

Medium 🟩 🟩

Improvement in Hair Loss, Strength, and Luster

Improvement in Brittle Nails

Skin Hydration, Elasticity, and Wrinkle Reduction

Joint Pain and Stiffness Reduction in Knee Osteoarthritis

Low 🟩

Increase in Lean Leg Mass in Trained Men

Glutathione and Taurine Substrate Support

Speculative 🟨

Healthspan Extension via Structural-Protein Replenishment

Connective Tissue and Tendon Resilience

Wound Healing and Skin Repair

Benefit-Modifying Factors

Potential Risks & Side Effects

High 🟥 🟥 🟥

Medium 🟥 🟥

Mild Gastrointestinal Effects

Low 🟥

Allergic Reaction (Wool, Feather, or Cysteine Sensitivity)

Sulfur Amino Acid Load in Specific Metabolic Disorders

Nutricosmetic Stack Interactions

Speculative 🟨

Pro-oxidant Effects at Supraphysiologic Cysteine Doses

Theoretical Iodine-Trapping Effects

Risk-Modifying Factors

Key Interactions & Contraindications

Risk Mitigation Strategies

Therapeutic Protocol

Discontinuation & Cycling

Sourcing and Quality

Practical Considerations

Interaction with Foundational Habits

Monitoring Protocol & Defining Success

Emerging Research

Conclusion